DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zp4qhh/pituitary_acth) has announced the addition of the "Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter-strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing's Disease)
- The report reviews key pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pituitary ACTH Hypersecretion (Cushing's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pituitary ACTH Hypersecretion (Cushing's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pituitary ACTH Hypersecretion (Cushing's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Companies Involved in Therapeutics Development
- Isis Pharmaceuticals, Inc.
- Ipsen S.A.
- Novartis AG
- Corcept Therapeutics Incorporated
- HRA Pharma, SA
- Cortendo Invest AB
- Orphagen Pharmaceuticals, Inc.
- ElexoPharm GmbH
Drug Profiles
- mifepristone
- ketoconazole
- pasireotide LAR
- LCI-699
- DG-3173
- ISIS-GCCRRx
- Next Generation Cortisol Inhibitor
- Small Molecule to Inhibit CYP11B1 for Cushing Disease
- Peptides to Antagonize ACTH Receptor for Cushing Syndrome
- Steroidogenic Factor-1 Antagonists
- Drug to Inhibit Melanocortin Receptor 2 for Cushing Disease
For more information visit http://www.researchandmarkets.com/research/zp4qhh/pituitary_acth
